Literature DB >> 18951214

Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma.

Suk-Joon Chang1, Woo Young Kim, Jong-Hyuck Yoon, Seung-Chul Yoo, Ki-Hong Chang, Hee-Sug Ryu.   

Abstract

OBJECTIVE: Surgical staging of endometrial carcinoma is practiced to identify the true extent of disease. The impact of para-aortic lymphadenectomy (PALD) on survival is unproven. The purpose of this study was to determine if a staging procedure that includes PALD is associated with improved survival in endometrial carcinoma patients who had been surgically staged.
DESIGN: Retrospective review of patients' records.
SETTING: Ajou University Hospital, a tertiary care hospital in South Korea. POPULATION: One hundred and sixty patients with endometrial carcinoma.
METHODS: We retrospectively analyzed a total of 160 FIGO stage I-III endometrial carcinoma patients without grossly metastatic para-aortic lymph nodes, who underwent surgery between 1994 and 2007. Exclusion criteria included presurgical radiation, stage IV disease and sarcomas. Two groups were identified: patients who underwent pelvic lymphadenectomy (PLD) and PALD (n=85) versus those who underwent PLD alone (n=75). Survival was analyzed using Kaplan-Meier method and Cox proportional hazards model. MAIN OUTCOME MEASURES: Disease-free and overall survival.
RESULTS: Overall, patients who underwent PALD demonstrated improved 5-year disease-free survival (81.0 vs 91.2%) and overall survival (85.8 vs 96.2%) compared to those who underwent PLD alone (p=0.019 and p=0.039, respectively). After multivariate analysis, patients' age (p=0.028), FIGO stage (p<0.001) and lymphadenectomy (p=0.014) were independent prognostic factors. The type of lymphadenectomy did not affect survival of low-risk patients. In intermediate to high-risk patients, PALD improved disease-free survival and showed a trend toward improvement of overall survival.
CONCLUSION: These data demonstrate that PALD has a potentially therapeutic benefit on survival in surgically staged patients with intermediate to high-risk endometrial carcinoma.

Entities:  

Mesh:

Year:  2008        PMID: 18951214     DOI: 10.1080/00016340802503054

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

1.  Current status in the management of uterine corpus cancer in Korea.

Authors:  Nan-Hee Jeong; Jong-Min Lee; Seon-Kyung Lee
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

2.  Lymphadenectomy should be performed up to the renal vein in patients with intermediate-high risk endometrial cancer.

Authors:  Ismail Alay; Taner Turan; Isin Ureyen; Alper Karalok; Tolga Tasci; Ahmet Ozfuttu; M Faruk Kose; Gokhan Tulunay
Journal:  Pathol Oncol Res       Date:  2015-01-07       Impact factor: 3.201

3.  The risk and pattern of pelvic and para aortic lymph nodal metastasis in patients with intermediate and high risk endometrial cancer.

Authors:  Praveen S Rathod; P N Shakuntala; V R Pallavi; Rajashekar Kundaragi; B Shankaranand; C R Vijay; K Uma Devi; Uttam D Bafna
Journal:  Indian J Surg Oncol       Date:  2014-03-28

4.  Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?

Authors:  Nina Bassarak; Thomas Blankenstein; Ansgar Brüning; Darius Dian; Florian Bergauer; Klaus Friese; Ioannis Mylonas
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

5.  Prognostic discrimination of subgrouping node-positive endometrioid uterine cancer: location vs nodal extent.

Authors:  D S Kapp; T K Kiet; J K Chan
Journal:  Br J Cancer       Date:  2011-09-13       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.